In this situation, RAS and MEK are elevated while tumor suppressors, such as PTEN, are decreased (47, 48), and BRAF/MEK inhibitor (trametinib and cobimetinib) combinations are now accepted as the standard treatment for resistant melanomas (49). The gene discussed is BRAF; the disease is neoplasm.